Antonio Bermejo Gómez

Head of CMC at Synartro

Antonio Bermejo Gómez has extensive work experience in the field of pharmaceutical research and development. Antonio is currently the Head of R&D and CMC at Synartro since 2022, responsible for overseeing research and development activities. Prior to this, they were the Head of CMC at Synartro from 2022 to 2023.

Before joining Synartro, Antonio worked at Oncopeptides AB as a CMC Project Manager from 2020 to 2022. In this role, they were responsible for coordinating and driving CMC activities in assigned projects, acting as the main point of contact for vendors and ensuring compliance with quality and regulatory requirements. Antonio also served as a Senior Staff Scientist, Medicinal Chemistry at Oncopeptides AB from 2020 to 2021, where they were involved in designing and synthesizing peptide-drug conjugates and establishing a new pre-clinical research facility.

Antonio's previous experience includes working as a Senior Scientist Medicinal Chemistry at Sprint Bioscience from 2018 to 2020, where they focused on fragment-based drug discovery and optimization of preclinical candidates. Antonio was also an Assistant Researcher at Stockholm University from 2017 to 2018, contributing to the research group of Prof. B. Martín-Matute.

Antonio's career began at AstraZeneca, where they held two postdoctoral researcher positions from 2015 to 2017. Antonio worked on the development of new fluorination methods for the synthesis of imaging biomarkers for PET and nucleophilic fluorinating reagents. Antonio also gained research experience as an Assistant Researcher and Postdoctoral Researcher at Stockholm University and as a Postdoctoral Researcher at Cambrex Karlskoga and Berzelii center EXSELENT, collaborating with various research groups.

Antonio completed their PhD at the Universidad de Sevilla and has teaching experience at the university level. Antonio also spent some time as a Visiting Researcher at the University of Bristol.

Antonio Bermejo Gómez received their education from the Universidad de Sevilla. From 2000 to 2005, they pursued their undergraduate studies in Chemistry and successfully graduated with a degree in Chemistry. Building upon their undergraduate education, they then pursued advanced studies in Chemistry from 2006 to 2007, obtaining a Master's degree in the field. Furthering their academic journey, Antonio completed their Doctor of Philosophy (PhD) in Chemistry from 2006 to 2011, solidifying their expertise in the subject.

Links

Previous companies

Stockholm University logo
University of Bristol logo
Sprint Bioscience logo
AstraZeneca logo

Org chart

Timeline

  • Head of CMC

    January, 2022 - present